US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Xref Limited (XF1) 銘柄情報

Xref Limited (XF1)

0.078

0.00

(0.00%)

終了 7月4日 3:00PM

Xref Limited (XF1) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.078

( - )

買値

0.06

売値

0.08

出来高

0.00

0.00 日の範囲 0.00

0.056 52 週間の範囲 0.20

時価総額

前日終値

0.078

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 179,424

発行済株式数

220,089,764

配当利回り

PER

-7.97

1 株当たり利益 (EPS)

-0.01

歳入

20.61M

純利益

-2.18M

Xref Limited engages in the development of human resources technology that automates pre-employment recruitment checks, employee engagement surveys, and exit interviews in Australia, Canada, the United Kingdom, New Zealand, and the United States. It operates in three segments: Xref Platform, Trust M... Xref Limited engages in the development of human resources technology that automates pre-employment recruitment checks, employee engagement surveys, and exit interviews in Australia, Canada, the United Kingdom, New Zealand, and the United States. It operates in three segments: Xref Platform, Trust Marketplace, and Xref Engage. The company provides pre-employment reference, pulse, and exit surveys through its enterprise and recruiter platform; ID verification, and qualification and background checks; and engagement surveys. The company serves not-for profit, health and aged care, construction, retail, and hospitality industries, as well as the government sector. Xref Limited is headquartered in Sydney, Australia. 詳細を表示

セクター

Technology

業界

Software & It Services

ウェブサイト

www.xref.com

本社

Sydney, Australia

設立

-

Xref Limited is listed in the Technology sector of the オーストラリア証券取引所 with ticker XF1. The last closing price for Xref was AUD0.08. Over the last year, Xref shares have traded in a share price range of AUD 0.056 to AUD 0.20.

Xref currently has 220,089,764 shares in issue. The market capitalisation of Xref is AUD17.17 million. Xref has a price to earnings ratio (PE ratio) of -7.97.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.013	20	0.065	0.085	0.065	277671	0.07071697	DE
4	0.016	25.8064516129	0.062	0.085	0.06	345355	0.06597213	DE
12	0.017	27.868852459	0.061	0.12	0.056	184559	0.06973332	DE
26	-0.082	-51.25	0.16	0.165	0.056	105654	0.07781162	DE
52	-0.082	-51.25	0.16	0.2	0.056	108129	0.13047786	DE
156	-0.097	-55.4285714286	0.175	0.23	0.056	273859	0.1641188	DE
260	-0.262	-77.0588235294	0.34	0.8	0.056	208965	0.24622381	DE

XF1 - Frequently Asked Questions (FAQ)

What is the current Xref Limited share price?

The current share price of Xref Limited is AUD 0.078

How many Xref Limited shares are in issue?

Xref Limited has 220,089,764 shares in issue

What is the market cap of Xref Limited?

The market capitalisation of Xref Limited is AUD 17.17M

What is the 1 year trading range for Xref Limited share price?

Xref Limited has traded in the range of AUD 0.056 to AUD 0.20 during the past year

What is the PE ratio of Xref Limited?

The price to earnings ratio of Xref Limited is -7.97

What is the cash to sales ratio of Xref Limited?

The cash to sales ratio of Xref Limited is 0.88

What is the registered address of Xref Limited?

The registered address for Xref Limited is 135 King Street, Sydney, New South Wales, 2000

What is the Xref Limited website address?

The website address for Xref Limited is www.xref.com

Which industry sector does Xref Limited operate in?

Xref Limited operates in the Software & IT Services sector

rosemountbomber

rosemountbomber 5分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

chereb19

chereb19 6分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

NASDAQ2020

NASDAQ2020 7分前

Im glad I held my shares past $0.15

Idunno

And don’t forget your buddy, AF. … .. .

Doc logic

Doc logic 8分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

rcaselli

rcaselli 8分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Idunno

Have at it Brazen! ;) … .. . :)

CatfishHunter

CatfishHunter 10分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

asp42001

asp42001 11分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

BigBadWolf

BigBadWolf 11分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

mgland

mgland 12分前

https://x.com/thommic/status/2072760144774005081

GTF

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

manibiotech

manibiotech 14分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

ErnieBilco

ErnieBilco 15分前

Good to know because I was thinking about letting it go but now I have a reason to hold

gdog

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

AngeloFoca

AngeloFoca 16分前

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

rmoss

Stay away stay very far away........

flipper44

flipper44 18分前

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

stoxjock

stoxjock 19分前

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

SC8

They didn't go to Europe. They're already there. It's an Italian company! Y90 has no shelf life. To do a trial outside of manufacturing continent is a complete waste of time, as RDGL has well demonstrated already. One company has competent leadership and one doesn't. One company is over 4 year

nowwhat2

nowwhat2 19分前

What're you waiting for ?......

Drink

https://investorshub.advfn.com/uimage/uploads/2026/7/3/eg[hqgutsi_group_for_health_logo.jpg

.

HillsideManor

HillsideManor 20分前

I believe it was published by a standard member, right after the microcap club conference in June. I'm hoping that will help get a lot more eyes on it.

Doc logic

Doc logic 20分前

flipper44,

Thanks for explaining this. Just to be clear for others, you are describing OS as an absolute number (can’t change) from the data in the trial. The comparator number is what can change based on the methods utilized to measure SOC/placebo benefit. This difference in measu

RafterAbarJ

RafterAbarJ 20分前

The interesting thing was the companies that thought Elite was too big for them to purchase. Makes me think that the acceptable sale price is significantly higher than where we are now. I’d like to know the number they have in mind.

HenryB3

HenryB3 21分前

The Scam is getting called out by alot of the bagholders now, eh? PUMP and DUMP city is where your at. The Path is south. Typical OTC lies and rumors. SUB 12 and that's being very nice!

Whats Cooking Group NVSA

Spectra Products

Antipa Minerals

55 North Mining

Southern Hemisphere Mining

Amundi DivDAX II UCITS ETF

Ausnet Services Holdings...

Levshares 3x Facebook Etp

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。